Ebola Vaccine is next for MDGMDG is working with the U.S. army to try and create the first ever Ebola vaccine. That is definitely worth a 2 cent jump in the stock price!
Wiz
Medicago announcesresearch collaboration for the development of a VLP vaccine candidatefor the prevention of Ebola with the U.S. Army Medical ResearchInstitute of Infectious Diseases (USAMRIID)
Medicago announcesresearch collaboration for the development of a VLP vaccine candidatefor the prevention of Ebola with the U.S. Army Medical ResearchInstitute of Infectious Diseases (USAMRIID)
Canada NewsWire
QUEBEC CITY, May 26, 2011
QUEBEC CITY, May 26, 2011 /CNW/ - Medicago Inc. (TSX: MDG), abiotechnology company focused on developing highly effective andcompetitive vaccines based on proprietary manufacturing technologiesand Virus-Like Particles (VLPs), today announced that it has enteredinto a research collaboration agreement with the U.S. Army MedicalResearch Institute of Infectious Diseases (USAMRIID) for thedevelopment of a plant-based VLP vaccine candidate for the preventionof Ebola. Ebola is a very serious hemorrhagic fever virus for which nolicensed treatment or vaccine exists.
"We are currently working on several other important infectious diseasetargets outside of influenza," said Louis Vezina, Chief ScientificOfficer of Medicago. "Our expertise in the development of VLP vaccinesusing our transient expression system, coupled with USAMRIID'sexperience and knowledge creates an ideal combination for the rapiddevelopment of a new generation of efficacious and competitive VLPvaccines."
Medicago's VLP plant-based technology is being utilized in multiplepreclinical and clinical trials. Medicago remains on track to reportfinal phase II clinical trial results for its H5N1 vaccine candidatethis quarter along with U.S. phase I clinical trial results for itsseasonal flu vaccine candidate.
About USAMRIID
USAMRIID, located at Fort Detrick, Maryland, is the lead medicalresearch laboratory for the U.S. Department of Defense's BiologicalDefense Research Program, and plays a key role in national defense andin infectious disease research. The Institute conducts basic andapplied research on biological threats resulting in medical solutions(such as vaccines, drugs and diagnostics) to protect the warfighter.While USAMRIID's primary mission is focused on the military, itsresearch often has applications that benefit society as a whole.USAMRIID is a subordinate laboratory of the U.S. Army Medical Researchand Materiel Command. For more information, visit www.usamriid.army.mil .
About Medicago
Medicago is a clinical-stage biotechnology company, developing effectiveand competitive vaccines based on proprietary Virus-Like Particles(VLP) and manufacturing technologies. Medicago is developing VLPvaccines to protect against pandemic and seasonal influenza, using atransient expression system which produces recombinant vaccine antigensin non-transgenic plants. This technology has potential to offeradvantages of speed and cost over competitive technologies. It coulddeliver a vaccine for testing in about a month after the identificationand reception of the genetic sequence. This production time frame hasthe potential to allow vaccination of the population before the firstwave of a pandemic strikes and to supply large volumes of vaccineantigens to the world market. Additional information about Medicago isavailable at www.medicago.com.
https://www.stockhouse.com/pfolio.aspx?frame=/pfolio_v2.asp%3Fpage%3Ddisplaynews%26portid%3D223677%26viewid%3D1%26newsid%3D14372700%26symbol%3DT.MDG%26fromalert%3D